Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Both the reduced heart death equivalents and improved quality of life outcomes demonstrated statistically significant favoring therapy in this subset analysis |
| We also expect positive news from business development activities |
| In summary, we have increased confidence in the potential of our autologous CardiAMP Cell Therapy program in both ischemic heart failure and in chronic myocardial ischemia, based on the data we have before us |
| Even as we have become aware that there were strong trends toward benefits across all patients with a 37% relative risk reduction on heart death equivalent and an 18% relative risk reduction in major adverse cardiac and cerebral vascular events or MACE, which are at the top of the list |
| It’s an advanced therapeutic opportunities and help offset our base operational costs |
| Further, all clinical outcomes included in this subset analysis favored cell therapy, including improved quality of life as measured using the Minnesota Living With Heart Failure Questionnaire, reduction of NT-proBNP levels, greater 6-minute walk distance and improved echocardiography parameters of left ventricular ejection fraction, left ventricular end systolic volume, and left ventricular and diastolic volume |
| In these patients, an analysis of all available data up to two years in the CardiAMP heart failure trial shows improvements over controls, including a 59% relative risk reduction in mortality and a 54% relative risk reduction of MACE |
| Stay healthy, be kind and have a wonderful day |
| A number of leading investigators, including both principal investigators in this trial believe that this to be the most compelling indication for this therapy |
| The CardiAMP Cell Therapy system has potential to be the first minimally invasive catheter based cell therapy available in Japan |
| Our net loss was approximately $2.6 million in Q3 2023 as compared to $3.1 million in Q3 2022 due primarily to increases in revenue coupled with reductions in research and development expenses during the quarter |
| This study is intended to build on three previous trials of mesenchymal stem cells in ischemic heart failure using the company’s proprietary Helix Delivery System, encompassing 93 patients treated with no treatment emergency, serious adverse events, and compelling early signals for benefit |
| In addition, the available interim data showed that for an important subset of patients who presented at the screening baseline visit with higher levels of NT-proBNP, a well-established biomarker of increased heart failure and stress to the heart |
| I want to thank everyone for participating in today’s call and for your interest in BioCardia and our primary mission to treat heart disease |
| And so we’ve looked at that interim data that’s available to us and analyzed it a number of different ways and it’s actually pretty robust that the patients with high NT-proBNP are just phenomenal responders |
| David? Thank you, Peter and good afternoon everyone |
| We look forward to sharing our continued progress |
| Thank you |
| Statement |
|---|
| We have since come to understand that the trial design and endpoint we were advancing were unlikely to be successful |
| Such factors include, among others, the inherent uncertainties associated with developing new products, technologies and obtaining regulatory approvals |
| This third quarter we were thrown a curveball when the Data Safety Monitoring Board for the CardiAMP heart failure trial or BCDA-01 recommended that we pause enrollment in the study |
Please consider a small donation if you think this website provides you with relevant information